Overview

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

GlaxoSmithKline

Treatments:

Dexamethasone
Pomalidomide